Abcam, a provider of life science research tools, agreed to acquire the Proteomics and Immunology business of Expedeon, a life sciences company, for €120m ($132m). "Abcam's growth strategy is committed to building out conjugation and assay capabilities. Expedeon's portfolio of products and technology, combined with Abcam's antibody and protein strengths, will put our company in a strong position to address the growing need for antibody conjugation and multiplexing solutions. We look forward to taking these innovation capabilities to market to provide a broader array of distinctive products for our customers," Alan Hirzel, Abcam CEO.